Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France (DIAPAZON)

• Evolution of Glycated hemoglobin (HbA1c) level, weight and the onset of hypoglycemic over time (2 years) for patients treated with Saxagliptin [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  HbA1c level <7% at Y2, weight and assessment of hypoglycaemic events after a 2-year exposure to Saxagliptin
• Joint population of Saxagliptin based on socio-demographic data, medical history, disease history, comorbidities including renal, hepatic and cardiac functions, HbA1c level at treatment initiation) [ Time Frame: One year (average) ] [ Designated as safety issue: No ]
• Utilization of Saxagliptin by General practitioners (GPs) and diabetologists in France (based on indication, initial dosage and adjustments, co-prescriptions, glycemic monitoring) [ Time Frame: During the treatment (Up to 2 years) ] [ Designated as safety issue: No ]
• Retention rate of Saxagliptin and to describe discontinuation rate and reasons [ Time Frame: At 2 years ] [ Designated as safety issue: Yes ]

• Evolution of Glycated hemoglobin (HbA1c) level, weight and the onset of hypoglycemic over time (2 years) for patients treated with Onglyza® [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  HbA1c level <7% at Y2, weight and assessment of hypoglycaemic events after a 2-year exposure to Onglyza®
• Joint population of Onglyza® based on socio-demographic data, medical history, disease history, comorbidities including renal, hepatic and cardiac functions, HbA1c level at treatment initiation) [ Time Frame: One year (average) ] [ Designated as safety issue: No ]
• Utilization of Onglyza® by General practitioners (GPs) and diabetologists in France (based on indication, initial dosage and adjustments, co-prescriptions, glycemic monitoring) [ Time Frame: During the treatment (Up to 2 years) ] [ Designated as safety issue: No ]
• Retention rate of Onglyza® and to describe discontinuation rate and reasons [ Time Frame: At 2 years ] [ Designated as safety issue: Yes ]

• Distribution of different hypoglycaemic therapeutic strategies used in France and characteristics of T2D patients depending on therapeutic strategies [ Time Frame: 2 month ] [ Designated as safety issue: No ]
• Saxagliptin utilization according to patient's profile and disease characteristics [ Time Frame: 24 month ] [ Designated as safety issue: No ]

• Distribution of different hypoglycaemic therapeutic strategies used in France and characteristics of T2D patients depending on therapeutic strategies [ Time Frame: 2 month ] [ Designated as safety issue: No ]
• Onglyza® utilization according to patient's profile and disease characteristics [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]

The purpose of this study is to respond to The French Health Authority which has requested BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with Saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety

Time Perspective: Ambispective cohort follow by a 18 to 24 month follow up period, Retrospective follow by Prospective.

The study will be proposed by GPs and diabetologists in France to ambulatory patients

Inclusion Criteria:

• Registry

  • Patient ≥ 18 years old
  • Patient with T2D

• Ambispective Cohort

  • Patient ≥ 18 years old
  • Patient with T2D
  • Patient initiated with Saxagliptin in the last 6 months before the inclusion or day of inclusion visit (whatever his/her ongoing hypoglycaemic treatment)
  • Patient agreeing to participate, and not yet enrolled by another physician

Exclusion Criteria:

• Patient participating in a clinical trial